| Home | E-Submission | Sitemap | Contact Us |  
JPTM > Ahead-of Print

doi: https://doi.org/10.4132/jptm.2020.05.15    [Epub ahead of print]
Immune landscape and biomarkers for immuno-oncology in colorectal cancers
Jeong Mo Bae , Seung-Yeon Yoo , Jung Ho Kim , Gyeong Hoon Kang
Department of Pathology, Seoul National University College of Medicine, Seoul, Korea
Corresponding Author: Gyeong Hoon Kang ,Tel: +82-2-740-8263, Fax: +82-2-765-5600, Email: ghkang@snu.ac.kr
Received: March 20, 2020;  Revised: May 13, 2020  Accepted: May 14, 2020.  Published online: June 26, 2020.
ABSTRACT
Recent advances in immuno-oncology have increased understanding of the tumor immune microenvironment (TIME), and clinical trials for immune checkpoint inhibitor treatment have shown remission and/or durable response in certain proportions of patients stratified by predictive biomarkers. The TIME in colorectal cancer (CRC) was initially evaluated several decades ago. The prognostic value of the immune response to tumors, including tumor-infiltrating lymphocytes, peritumoral lymphoid reaction, and Crohn’s-like lymphoid reaction, has been well demonstrated. In this review, we describe the chronology of TIME research and review the up-to-date high-dimensional TIME landscape of CRC. We also summarize the clinical relevance of several biomarkers associated with immunotherapy in CRC, such as microsatellite instability, tumor mutational burden, POLE/POLD mutation, consensus molecular subtype, and programmed death-ligand 1 expression.
Key Words: Colorectal neoplasms; Tumor immune microenvironment; Immunotherapy; Microsatellite instability
TOOLS
PDF Links  PDF Links
Full text via DOI  Full text via DOI
Download Citation  Download Citation
CrossRef TDM  CrossRef TDM
  E-Mail
Share:      
METRICS
0
Crossref
0
Scopus
282
View
25
Download
Related article